NCT04629729 2025-12-11
FT819 in Subjects With B-cell Malignancies
Fate Therapeutics
Phase 1 Active not recruiting
Fate Therapeutics
Fate Therapeutics
Gilead Sciences
MedImmune LLC
Teva Branded Pharmaceutical Products R&D, Inc.
Shandong Lanjin Pharmaceuticals Co.,Ltd